11/20
11:12 am
pdsb
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround [Yahoo! Finance]
Low
Report
Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround [Yahoo! Finance]
11/15
03:26 pm
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
11/15
02:22 am
pdsb
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... [Yahoo! Finance]
High
Report
PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... [Yahoo! Finance]
11/14
08:12 am
pdsb
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
High
Report
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
11/14
08:00 am
pdsb
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results
High
Report
PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results
11/9
02:07 am
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
PDS Biotechnology Co. (NASDAQ: PDSB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/9
02:07 am
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
PDS Biotechnology Co. (NASDAQ: PDSB) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/6
08:00 am
pdsb
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time
Low
Report
PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time
11/1
11:06 pm
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
PDS Biotechnology Co. (NASDAQ: PDSB) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
10/24
08:08 am
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
10/22
01:57 pm
pdsb
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know [Yahoo! Finance]
Low
Report
PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know [Yahoo! Finance]
10/22
08:00 am
pdsb
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine
Low
Report
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine
10/2
11:20 am
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
High
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
10/2
08:00 am
pdsb
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
Medium
Report
PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation
9/23
10:42 am
pdsb
PDS Biotechnology: Continuing The Holding Pattern [Seeking Alpha]
Low
Report
PDS Biotechnology: Continuing The Holding Pattern [Seeking Alpha]
9/17
08:02 am
pdsb
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Low
Report
PDS Biotechnology Co. (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
9/16
07:00 am
pdsb
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024
Medium
Report
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024
9/9
08:00 am
pdsb
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
Low
Report
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024
9/3
08:00 am
pdsb
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference
High
Report
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference